With an all-virtual format, the 39th Annual J.P. Morgan Healthcare Conference was significantly different from years past, but it still offered ample opportunity for good discussion on a number of key topics in our industry including COVID-19 therapeutics, oncology R&D and the future outlook for the biopharmaceutical industry. Several members of the Takeda leadership team participated in panels, while Christophe Weber, president and chief executive officer, provided a company update on the progress of our continued transformation and the pipeline strategy fueling our growth.
Update on Pipeline Strategy and Financial Strength
During his presentation, Christophe Weber emphasized that as a values-based and R&D-driven biopharmaceutical company celebrating its 240 year anniversary in 2021, Takeda remains committed to building on its heritage and delivering on its highly innovative pipeline and business imperatives to positively impact our patients, people and the planet. This includes rapidly translating science into innovative medicines to improve lives worldwide, creating an exceptional experience for Takeda’s global colleagues, fulfilling our responsibility to protect the planet and unleashing the power of data and digital capabilities to become the most trusted, data-driven outcomes-based biopharmaceutical company.
By delivering on these imperatives, we expect to reach our goal of JPY5 trillion ($47 billion) revenue by FY20301, representing 50% growth from FY2019. Christophe also discussed how Takeda’s world-class R&D engine—which has generated a modality diverse pipeline of approximately 40 clinical-stage new molecular entities (NMEs) and includes key assets with several near-term pivotal milestones—will potentially deliver transformative new treatments to address critical unmet patient needs and contribute to our dynamic growth. Listen to Christophe’s full presentation here.
The Biopharmaceutical Industry Outlook in 2021
In a panel hosted by J.P. Morgan, Ramona Sequeira, president, United States Business Unit and Global Portfolio Commercialization, talked with industry peers about the role of the biopharmaceutical industry in 2021 as the U.S. prepared for a new presidential administration while it continues to manage the impact of COVID-19. Ramona noted the importance of continuous collaboration within the healthcare industry and across government entities to maximize an efficient response to COVID-19, but also to help address the rapidly rising healthcare costs that patients currently face. Ramona emphasized Takeda’s commitment to collaboration, and data and analytics to better address patient access and affordability, adding that under the new administration, “the dialogue on patient affordability and accessibility will continue, and we need to work together to create change and lower patients’ costs.”
Collaboration Across COVID-19 Therapeutic Development
Julie Kim, president, Plasma-Derived Therapies Business Unit, joined FiercePharma alongside other industry leaders to discuss the importance of developing new therapeutics to treat patients with COVID-19. As we continue to learn more about how the disease impacts different populations, it is critical to have different treatments and vaccines available, and Julie emphasized how collaboration across the industry was—and still is—essential in our collective response. For example, Takeda has partnered with other world-leading plasma companies to develop a potential hyperimmune globulin for patients with COVID-19. Julie noted this type of industry collaboration is key to drug discovery for COVID-19 and beyond, and it is likely here to stay: “I think it can be quite powerful when different groups come together and work towards a certain objective for patients worldwide.”
Data and Innovation in Cancer R&D
Andy Plump, president, Research & Development, and other R&D leaders, joined Endpoints News to discuss new developments in cancer treatment, one of the most rapidly advancing areas of the industry over the past decade. Andy called for greater efficiency and innovation, noting that we may yield better results for patients if we align the many active workstreams across the industry. Additionally, if the industry comes together in oncology R&D to apply collaborative techniques, such as critical data sharing, we could develop stronger analytics and artificial intelligence tools to create better and more innovative treatments for patients. As Andy emphasized, delivering innovative treatment options that address unmet needs is a core focus for Takeda and central to our R&D efforts in oncology.
Throughout the J.P. Morgan Healthcare Conference, industry innovation and business transformation were thematic through lines. At Takeda, our unwavering commitment to our purpose – better health for people, brighter future for the world – inspires and guides us as we continue on this journey of transforming our business and innovating in a way that makes a positive impact on patients, people and the planet.
1 Includes incremental revenues on a non-PTS (probability of technical success) basis (i.e., figures represent best case scenarios, including technical success that Takeda does not currently consider probable to occur and should not be seen as a forecast or target figure). On a PTS-adjusted basis, Takeda expects revenue CAGR to be in the low single digits between FY2019 and FY2030. Does not include any potential impacts imposed by the Most Favored Nation Model interim final rule issued by the U.S. Centers for Medicare & Medicaid Services (CMS) on November 20, 2020, which are currently being assessed.